Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
About this item
Full title
Author / Creator
Brück, Wolfgang , Pförtner, Ramona , Pham, Trinh , Zhang, Jingya , Hayardeny, Liat , Piryatinsky, Victor , Hanisch, Uwe-Karsten , Regen, Tommy , van Rossum, Denise , Brakelmann, Lars , Hagemeier, Karin , Kuhlmann, Tanja , Stadelmann, Christine , John, Gareth R. , Kramann, Nadine and Wegner, Christiane
Publisher
Berlin/Heidelberg: Springer-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer-Verlag
Subjects
More information
Scope and Contents
Contents
Laquinimod (LAQ) is a new oral immunomodulatory compound that reduces relapse rate, brain atrophy and disability progression in multiple sclerosis (MS). LAQ has well-documented effects on inflammation in the periphery, but little is known about its direct activity within the central nervous system (CNS). To elucidate the impact of LAQ on CNS-intrin...
Alternative Titles
Full title
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3422618
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3422618
Other Identifiers
ISSN
0001-6322
E-ISSN
1432-0533
DOI
10.1007/s00401-012-1009-1
